Compare Campbell Soup Co. (CPB) vs Novo Nordisk A/S (NVO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Campbell Soup Co. vs Novo Nordisk A/S — how do they compare? Campbell Soup Co. trades at $22.65 (market cap $6.78B), while Novo Nordisk A/S trades at $46.23 (market cap $207.85B). The key difference: Novo Nordisk A/S is far larger — about 30.7× Campbell Soup Co.'s market cap, and Campbell Soup Co. pays the higher dividend (6.87%). Which is the better fit depends on your goals.
| CPB | NVO | |
|---|---|---|
Market Cap | $6.78B | $207.85B |
Sector | Consumer Staples | Health |
52-Week High | $34.03 | $63.98 |
52-Week Low | $20.00 | $35.29 |
Enterprise Value | $13.38B | $222.55B |
Dividend Yield | 6.87% | 3.81% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Campbell's (CPB) trades at $22.56, up 0.6% with bullish technical signals and mixed fundamentals. The stock shows strong valuation metrics with P/E of 11.1 and P/S of 0.7, while recent earnings beat expectations in Q1 2026. Revenue growth remains modest at $10.3B in 2025, though net margins compressed to 5.9%. Technical indicators suggest bullish momentum with support at $22 and resistance at $23.
CPB offers a compelling 7% dividend yield supported by stable cash flows, but faces margin pressure and analyst skepticism with only 3% buy ratings. The company's cost-saving initiatives and new product launches provide potential upside, though competitive pressures and consumer spending trends remain key risks for sustained growth.
Novo Nordisk (NVO) trades at $46.28, down 3.05% today, with technical indicators showing neutral signals. The company maintains strong fundamentals with Q2 2026 EPS beating expectations at $0.96 versus $0.77 estimate, continuing a pattern of earnings outperformance. Revenue growth remains solid with 2025 revenue reaching $309.1B and net income margin of 33.14%. Analyst sentiment remains positive with 57.9% recommending Buy, though recent news highlights competitive pressures from Eli Lilly in the GLP-1 market.
NVO presents a compelling investment case with robust profitability metrics including 59.82% ROE and attractive valuation at 11.62 P/E. However, increasing competition in weight-loss drugs and pricing pressures create headwinds. The stock's current technical neutrality suggests potential consolidation near current levels, with fundamental strength supporting long-term growth prospects despite near-term competitive challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Campbell Soup Co.
With a history that dates back around 150 years, Campbell Soup is now a leading manufacturer and marketer of branded convenience food products, most notably soup. The firm's product assortment includes well-known brands like Campbell's, Pace, Prego, Swanson, V8, and Pepperidge Farm. Following the sale of its international snacking operations, which wrapped in calendar 2019, the firm derives nearly all of its sales from its home turf. Campbell has made a handful of acquisitions to reshape its product mix the past few years, including the tie-up with Snyder's-Lance (completed in March 2018), which enhances its exposure to the faster-growing on-trend snack food aisle, complementing its Pepperidge Farm lineup.
Read more on CPB →About Novo Nordisk A/S
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →
